1. Home
  2. LCLN vs ANNX Comparison

LCLN vs ANNX Comparison

Compare LCLN & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lincoln International Inc. Class A Common Stock

LCLN

Lincoln International Inc. Class A Common Stock

SELL

Current Price

$27.38

Market Cap

821.7M

Sector

Finance

ML Signal

SELL

Logo Annexon Inc.

ANNX

Annexon Inc.

SELL

Current Price

$3.57

Market Cap

726.1M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
LCLN
ANNX
Founded
1996
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
821.7M
726.1M
IPO Year
2026
2020

Fundamental Metrics

Financial Performance
Metric
LCLN
ANNX
Price
$27.38
$3.57
Analyst Decision
Buy
Buy
Analyst Count
7
10
Target Price
★ $28.36
$17.00
AVG Volume (30 Days)
287.5K
★ 3.6M
Earning Date
11-05-2026
11-09-2026
Dividend Yield
★ 1.03%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$30.02
N/A
Revenue Next Year
$16.81
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$20.05
$2.99
52 Week High
$28.71
$7.18

Technical Indicators

Market Signals
Indicator
LCLN
ANNX
Relative Strength Index (RSI) 60.84 38.21
Support Level $22.92 $3.49
Resistance Level $27.90 $4.42
Average True Range (ATR) 1.32 0.28
MACD 0.16 -0.02
Stochastic Oscillator 71.26 2.63

Price Performance

Historical Comparison
LCLN
ANNX

About LCLN Lincoln International Inc. Class A Common Stock

Lincoln International Inc is an independent investment banking advisory company focused on private capital markets. The company operates its business through its two operating segments: Investment Banking Advisory and Valuations and Opinions. The Investment Banking Advisory segment offers a range of services related to mergers and acquisitions, with key areas of focus including sell-side advisory, buy-side advisory, asset sales and divestitures, restructuring, primary and secondary capital raising, and merger-related engagements. The Valuations and Opinions segment provides valuation services to investment funds and financial institutions. The majority of revenue is derived from the Investment Banking Advisory segment. Geographically, the maximum revenue is derived from the Americas.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: